Merck KGaA 보도자료 - 뉴스와이어

기업 뉴스룸

Merck KGaA

제약

뉴욕증권거래소 MRK

Frankfurter Str. 250 64293 Darmstadt Germany

Merck KGaA 보도자료

메일구독 RSS

39개

10월 30일 17:37

Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate

Merck, a leading science and technology company, today announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Hengrui). The partnership includes an exclusive license worldwide (ex-China) to develop, manufacture and comm...

건강 제약 병원/의료 제휴

10월 16일 15:35

Merck to Present Latest Research from Oncology Portfolio at ESMO 2023

Merck, a leading science and technology company, today announced that 28 abstracts featuring the latest research on the company’s oncology portfolio addressing unmet needs across bladder, head and neck, lung, colorectal and other cancers, will be ...

건강 제약 병원/의료 조사연구

10월 11일 15:38

Evobrutinib, CNS-Penetrant BTKi, Has Shown Sustained Clinical Benefit Up to Five Years in People with RMS

Not intended for UK and U.S. based media Merck, a leading science and technology company, today announced new five-year data from the open-label extension (OLE) of the Phase II clinical trial, which demonstrated that people with relapsing multiple...

건강 제약 병원/의료 조사연구

10월 10일 15:59

Merck Presents New MAVENCLAD® (Cladribine Tablets) Data Highlighting Sustained Reduction in NfLs and Benefit of Early Initiation

Not intended for UK and U.S. based media Merck, a leading science and technology company, today announced the presentation of new analyses from the MAVENCLAD® (cladribine tablets) MAGNIFY-MS study, which demonstrated that patients with relapsing m...

건강 제약 의학 조사연구

10월 6일 11:04

Merck Launches New Collaboration with United Nations-Guided Global Initiative on Ageing to Support Carers

Merck, a leading science and technology company, today announced a new collaboration with the United Nations-Guided Global Initiative on Ageing (GIA) to provide a training course on critical skills for family carers. The course, consisting of 5 mo...

건강 제약 병원/의료 제휴

9월 20일 14:29

Merck Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery

Merck, a leading science and technology company, today announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence (AI)-driven design and discovery capabilities, further advancing the company’s re...

IT 인터넷 건강 제약 제휴

5월 26일 11:55

Merck Highlights Commitment to Improving Cancer Outcomes at ASCO 2023

Merck, a leading science and technology company, today announced that 43 abstracts covering several modalities and mechanisms will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, Chicago, Ill., US. N...

건강 의학 조사연구

4월 12일 16:30

Initiation of New Patients on Evobrutinib Paused in the U.S.; Fully Enrolled Phase III Evobrutinib Studies Continue

Merck, a leading science and technology company, today announced the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the initiation of new patients on evobrutinib and patients with less than 70 days exposure to study ...

건강 제약 조사연구

3월 28일 09:40

Merck Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights to Anti PD-L1 Antibody BAVENCIO® (avelumab)

Merck today announced it has strengthened its Oncology franchise by regaining exclusive worldwide rights to develop, manufacture, and commercialize anti-programmed death ligand-1 (PD-L1) antibody BAVENCIO® (avelumab) following the termination of t...

건강 제약 사업계획

2월 24일 09:10

Merck Highlights New Four-Year Efficacy and Safety Data for Investigational BTK Inhibitor, Evobrutinib, in RMS

Not intended for UK and U.S. based media Merck, a leading science and technology company, today announced updated long-term efficacy and safety data for investigational evobrutinib that continue to show a favorable safety and tolerability profile,...

건강 제약 조사연구

2월 14일 08:55

New Analyses Reinforce Survival Benefit of BAVENCIO First-Line Maintenance Treatment in Patients With Advanced Urothelial Carcinoma

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced findings of a new analysis of long-term follow-up data from the Phase III JAVELIN Bladder 100 trial. These analyses reinforce the proven survival benefits of...

건강 제약 병원/의료 조사연구

2022년 12월 23일 09:25

Merck Announces Collaboration with Mersana Therapeutics to Develop Novel Immunostimulatory Antibody-Drug Conjugates

Merck, a leading science and technology company, today announced a research collaboration and commercial license agreement with Mersana Therapeutics, Inc., Cambridge, Massachusetts, USA to discover novel antibody-drug conjugates (ADCs) leveraging ...

건강 제약 병원/의료 제휴

2022년 11월 22일 13:45

Merck Aims to Double R&D Productivity in Oncology, Neurology and Immunology to Deliver More Medicines to Patients Faster

Merck, a leading science and technology company, today shared updates on the company’s healthcare research and development strategy, aimed at doubling R&D productivity. To achieve the goal of introducing one new product or major indication every 1...

건강 제약 병원/의료 사업계획

2022년 10월 26일 17:25

Merck Showcases Depth of MS Portfolio at ECTRIMS Supporting Commitment to Advancing MS Care

Merck, a leading science and technology company, today announced it will present 39 abstracts at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held October 26-28, 2022 in Amsterdam, t...

건강 제약 병원/의료 조사연구

2022년 10월 26일 16:57

Merck Highlights New Data for Evobrutinib, First BTKi to Demonstrate Sustained Clinical Benefit for People with RMS through Three and a Half Years of Treatment

Merck, a leading science and technology company, today announced findings which demonstrated that annualized relapse rates (ARR) remained low and Expanded Disability Status Scale (EDSS) scores were stable in people with relapsing multiple sclerosi...

건강 제약 병원/의료 조사연구

2022년 9월 22일 15:00

Merck Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor

Merck, a leading science and technology company, today announced a collaboration agreement with licensing option with Nerviano Medical Sciences S.r.l. (NMS) for the next-generation highly selective and brain-penetrant PARP1 (poly (ADP-ribose) poly...

건강 제약 제휴

2022년 9월 8일 16:50

Xevinapant Five-Year Data Show Survival Rate Nearly Doubled in Patients with Unresected LA SCCHN, When Added to Standard of Care

Merck, a leading science and technology company, today announced that the IAP (inhibitor of apoptosis protein) inhibitor xevinapant (formerly known as Debio 1143) plus chemoradiotherapy (CRT) markedly improved long-term efficacy outcomes in patien...

건강 제약 병원/의료 조사연구

2022년 9월 8일 16:50

Merck to Highlight Data at ESMO 2022 with Potential for Transformative Impact on Cancer Patients

Merck, a leading science and technology company, today announced the latest research from the Company’s oncology portfolio and pipeline to be presented at this year’s European Society of Medical Oncology (ESMO) Annual Meeting, September 9-13, 2022...

건강 제약 병원/의료 조사연구

2022년 6월 7일 11:30

Merck Advances Development Programs in Oncology Focusing on Novel Mechanisms and Pathways

Merck, a leading science and technology company, today provided an update on the progress of the company’s innovative oncology development pipeline focused on DNA damage biology. With clinical programs designed to further advance standards of care...

건강 제약 바이오테크 개발

2022년 5월 27일 10:10

Merck to Present Latest Research From Oncology Portfolio at ASCO 2022

Merck, a leading science and technology company, today announced the latest research representing the Company’s innovative oncology portfolio has been accepted for presentation at this year’s American Society of Clinical Oncology (ASCO) Annual Mee...

건강 제약 병원/의료 조사연구

2022년 4월 4일 09:30

Merck Shares Advances in MS Portfolio with Key Efficacy and Safety Data at AAN 2022

DARMSTADT, Germany--(BUSINESS WIRE)-- Merck, a leading science and technology company, today announced 13 abstracts from the Company’s multiple sclerosis (MS) portfolio will be presented at the 2022 American Academy of Neurology (AAN) Annual Meeti...

건강 제약 바이오테크 투자

2022년 3월 2일 10:05

Glucophage® Is the First Oral Diabetes Treatment Approved in Europe for Use During Pregnancy

Merck, a leading science and technology company, today announced in a European worksharing procedure (WSP) an extension to the label for metformin products in the EU - Glucophage® (metformin hydrochloride [HCL] immediate release), Glucophage XR® (...

건강 제약 병원/의료 개발

2022년 2월 25일 09:25

New MAVENCLAD® Data at ACTRIMS Forum 2022 Show Favourable Efficacy Outcomes Versus Other Oral DMTs and Lower Occurrence of Further Relapses or Disability Progression

Merck, a leading science and technology company, today announced new real-world data from the MSBase Registry demonstrating MAVENCLAD® (cladribine tablets) had more favourable relapse outcomes and longer time to switch to another disease modifying...

건강 제약 병원/의료 조사연구

2022년 2월 21일 11:55

European Commission Approves TEPMETKO® (tepotinib) for Patients with Advanced NSCLC with METex14 Skipping Alterations

Merck, a leading science and technology company, today announced that the European Commission (EC) has approved once-daily oral TEPMETKO® (tepotinib) as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCL...

건강 제약 병원/의료 개발

2022년 2월 21일 11:30

Long-Term Follow-Up Data Reinforce Continued Overall Survival Benefit of BAVENCIO® (avelumab) First-Line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma

Merck, a leading science and technology company, today announced the results of an exploratory analysis from the Phase III JAVELIN Bladder 100 trial with 19 additional months of follow-up data from the initial primary analysis. This analysis reinf...

건강 제약 병원/의료 조사연구